Cargando…
Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
Autor principal: | Heo, Young-A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267539/ https://www.ncbi.nlm.nih.gov/pubmed/31186609 http://dx.doi.org/10.1007/s40267-018-0576-1 |
Ejemplares similares
-
Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018) -
Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022) -
Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018) -
Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022) -
Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)